| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1835 | Dndi-0690 | Novel antitubercular and antiparasitic agent, possessing excellent in vitro activity against both L. donovani and Leishmania infantum as well as displaying a better safety profile |
|
| DCC1836 | Do-601 | Analeptic agent, stimulating central nervous system; Anti-barbiturate-overdose |
|
| DCC1837 | Dolastatin 10 Featured | Highly potent cytotoxic microtubule inhibitor |
|
| DCC1838 | Doot-2d | Selective MAO-B inhibitor |
|
| DCC1839 | Dora 42 | Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA) |
|
| DCC1840 | Doramectin | Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle |
|
| DCC1841 | Dothiepin Hydrochloride | Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects |
|
| DCC1842 | Dov51892 | Agonist of GABAA receptors α15 subunits |
|
| DCC1843 | Dp-326 | Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections |
|
| DCC1844 | Dpa-154 | Novel effective and selective inhibitor of E. coli topoisomerase I |
|
| DCC1845 | Dpb163-ae | Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum. |
|
| DCC1846 | Dpbx-l-dopa | Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors |
|
| DCC1847 | Dp-c-1 | Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP |
|
| DCC1848 | Dpf-p10 | First Potent Small Molecule Ligand for MALAT1 |
|
| DCC1849 | Dpi-287 | Novel highly selective agonist for the δ-opioid receptor, producing less convulsions than most drugs from this family and having antidepressant-like effects |
|
| DCC1850 | Dpp7-in-5385 | Novel inhibitor of dipeptidyl peptidase 7 (DPP7) |
|
| DCC1851 | Dpp8/9-in-8j | Novel selective DPP8/9 inhibitor, blocking AML progression in vivo |
|
| DCC1852 | Dppe Hydrochloride | Substrate of CYP3A and inhibitor of P-glycoprotein |
|
| DCC1853 | Dpre1-in-377790 | Novel DprE1 inhibitor, killing M. tuberculosis |
|
| DCC1854 | D-propargylglycine | Click chemistry tool molecule in probing peptidoglycan (PG) |
|
| DCC1855 | Dp-v-4 | Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP |
|
| DCC1856 | Dri-c23041 | Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV |
|
| DCC1857 | Dri-c91005 | Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV |
|
| DCC1858 | Dropropizine | Oral non-opioid anti-tussive agent for treatment of cough |
|
| DCC1859 | Drostanolone Propionate | Inhibitor of the growth of estrogen receptor-presenting breast cancers |
|
| DCC1860 | Ds08210767 | Novel potent PTHR1 antagonist |
|
| DCC1861 | Ds19161384 | Novel selective PPARγ modulator, resulting in robust plasma glucose reductions with excellent DMPK profiles |
|
| DCC1862 | Ds28120313 | Novel potent orally active hepcidin production inhibitor |
|
| DCC1863 | Ds37571084 | Novel and orally bioavailable PTHR1 antagonist |
|
| DCC1864 | Ds-3801b Hydrochloride | Novel non-macrolide GPR38 agonist |
|
